San Francisco, CA, United States of America

Graeme Ian Bell


Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 286(Granted Patents)


Company Filing History:


Years Active: 1985-2005

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations of Graeme Ian Bell in Biotechnology

Introduction

Graeme Ian Bell, an accomplished inventor based in San Francisco, CA, has made significant contributions to the field of biotechnology. With a total of eight patents, his work has focused on groundbreaking developments in molecular biology, particularly in the area of growth factors and enzymatic functions.

Latest Patents

Among Graeme Ian Bell's latest patents are two notable inventions. The first is related to "Recombinant PDGF A-chain homodimers and methods of use," which includes DNA encoding two forms of PDGF A-chain polypeptide. This patent details the construction of expression vectors that facilitate the expression of such DNA in yeast and mammalian cells. Furthermore, it describes methods for producing active PDGF A-chain homodimer and active PDGF A-chain/B-chain heterodimer. The second patent focuses on the "Manganese superoxide dismutase cloning and expression in microorganisms," showcasing innovative techniques in enzyme expression and utilization.

Career Highlights

Graeme Ian Bell is currently associated with Chiron Corporation, a leading biotech company known for its development of novel therapeutics and vaccines. His extensive work in the realm of recombinant proteins and growth factors highlights his expertise and dedication to advancing medical science.

Collaborations

Throughout his career, Graeme has collaborated with esteemed scientists such as Carl-Henrik Heldin and Christer Betsholtz. These partnerships have facilitated the exchange of ideas and fostered innovative research, further enhancing the impact of their collective work in biotechnology.

Conclusion

Graeme Ian Bell stands out as a pivotal figure in the biotechnological innovation landscape. His patents not only demonstrate his inventive prowess but also contribute to significant advancements in therapeutic development. As he continues to work at Chiron Corporation, the future holds promise for further groundbreaking discoveries in his field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…